Conradt A, Weidinger H, Algayer H
Geburtshilfe Frauenheilkd. 1984 Feb;44(2):118-23. doi: 10.1055/s-2008-1036865.
Retrospectively the 4,905 single pregnancies of the four years 1979-1982 are divided into 882 (18.0%) patients treated by tocolysis and 4,023 (82.0%) patients treated without tocolysis (R). The patients with tocolysis (BMG) received in addition to the Betamimectic agents since 1979 a low dose of magnesium (feto- longoral ) to protect the heart (3-6 mval Mg ++) daily and since early in 1981 to assist in the tocolysis 30 to 40 mval Mg ++ daily in the oral from of magnesium aspartate (Mg 5- Longoral ). The incidence of pre-eclampsia (G) in the groups BMG and R is recorded. The R group constitutes the normal group (N) by substracting the group G. Compared were in the groups NG and BMG the mean age and parity, the incidence of adjuvant magnesium medication, the duration of pregnancy and the incidence of intra-uterine growth retardation ( IUR ). The incidence of pre-eclampsia (G) in the 882 patients treated with Betamimetics and magnesium was 0. In the other 4,093 patients the incidence was 97 (2%). The rate of intra-uterine growth (lower than the 10% BPE ) was 9.4% in the 3,093 normal patients, 45.4% in the 97 patients with pre-eclampsia and in the 398 BMG patients of the years 1979 and 1980 with the small addition of magnesium (BMG 1) the incidence was 17.8%. In the 484 patients of the years 1981 and 1982, with large additional doses of magnesium (BMG 2) the incidence was 10.1%. The correlation of the intra-uterine growth retardation degrees (lower than 25% Hohenauer , 10% BPE ) was highest in the group G (1.3:1).(ABSTRACT TRUNCATED AT 250 WORDS)
回顾性地将1979 - 1982年这四年间的4905例单胎妊娠分为882例(18.0%)接受宫缩抑制剂治疗的患者和4023例(82.0%)未接受宫缩抑制剂治疗的患者(R组)。自1979年起,接受宫缩抑制剂治疗的患者(BMG组)除使用β拟交感神经药物外,每天还接受低剂量镁剂(胎儿长效口服)以保护心脏(3 - 6毫当量镁离子),自1981年初起,为协助宫缩抑制,每天口服30至40毫当量的天冬氨酸镁(Mg 5 - Longoral)形式的镁剂。记录BMG组和R组中先兆子痫(G组)的发生率。通过减去G组,R组构成正常组(N组)。比较NG组和BMG组的平均年龄、产次、辅助使用镁剂的发生率、妊娠持续时间以及宫内生长迟缓(IUGR)的发生率。接受β拟交感神经药物和镁剂治疗的882例患者中先兆子痫(G组)的发生率为0。在其他4093例患者中,发生率为97例(2%)。3093例正常患者的宫内生长率(低于第10百分位BPE)为9.4%,97例先兆子痫患者为45.4%,1979年和1980年使用少量镁剂的398例BMG组患者(BMG 1组)发生率为17.8%。1981年和1982年使用大量额外镁剂的484例患者(BMG 2组)发生率为10.1%。宫内生长迟缓程度(低于25%Hohenauer,10%BPE)的相关性在G组中最高(1.3:1)。(摘要截取自250字)